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Introduction
ver the last 20 years, there has been a growing interest in the potential beneficial effects of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) in chronic obstructive pulmonary disease (COPD) (1) (2) (3) (4) (5) .
The clinical studies suggest that statin therapy may confer a number of benefits in COPD such as reducing both the frequency of, and mortality from, infective exacerbations, reducing mortality from pneumonia, reduced decline in lung function and reduced risk of lung cancer (1, 2, 4) . While the benefits of statin therapy in COPD can be rationally explained by the known pharmacological effects of statins on the lungs (5, 6) and justified where co-morbid cardiac disease commonly exists (1, 7) . O Baay, The Role of atorvastatin in the treatment of COPD ….
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The basis of the systemic inflammation in COPD comes from two possibilities; either 'spill-over' effect from inflammation driven primarily in the lungs in response to aero-pollutants chiefly cigarette smoke exposure, neutrophilic inflammation and recurrent infection (8) or inherent systemic-based pro-inflammatory state conferred by a genetic disposition (1, 9) . Smoking significantly enhances (possibly unmasking) this inflammatory disposition by being a recurring pro-inflammatory stimulus to the pulmonary and immune systems. This possibility is supported by data showing that poor lung function (reduced forced expiratory volume in 1 second (FEV1)), independent of smoking, predicts poor vascular and respiratory outcomes (10, 11) . Conversely normal lung function, even after decades of smoking exposure, confers a greater 'degree of protection' from cardiorespiratory outcomes than that observed in those with poor lung function who have been lifelong non-smokers. These observations raise the possibility that systemic inflammation could be a secondary driver of inflammation in the bronchial epithelium alongside that derived from smoke exposure ('reverse' effect) (11, 12) . Given that statins have been shown to lower systemic inflammation through inhibition of the inflammatory pathways mediated by NF-κB and IL-6 (13) . It is no surprise that statins are now considered effective anti-inflammatory agents, lowering systemic markers (IL-6 and Creactive protein (CRP)) by over 50% in a matter of days (13, 14) . It should not be forgotten that statins also possess important anti-apoptotic, anti-oxidant and anti-proliferative effects, whether these are independent of their antiinflammatory effects is not known (14) . In the treatment of COPD, while currently recommended therapy for COPD is primarily inhaler-based, where the aim is to reduce symptoms, improve quality of life and reduce hospitalization, this approach does not substantially change disease progression or reduce mortality (15) . More importantly, these treatments do not improve the many and varied systemic manifestations of COPD. The only oral medication for COPD is roflumilast, which is limited to severe disease characterized by recurrent acute exacerbations of COPD (16, 17) . This study is a clinical trial to assess the efficacy and safety of statin therapy in 2 different doses (high vs. low dose vs. placebo) for COPD patients with evidence of inflammatory markers as high sensitivity CRP (HsCRP) in term of severity, hospitalization and mortality.
Methods
Ninety patients from both genders were included in the study, whom age from 40 years and above. They were treated at the outpatient private clinic in Babylon government, Iraq, during the period from September 2012 to April 2016. Inclusion criteria considered any patients with diagnosis of COPD by consistent history of smoking, clinical manifestation with spirometric criteria and high resolution computerized tomography (HRCT) findings who don't have any other diseases like ischemic heart disease, diabetes mellitus, hypertension or dyslipidemia neither before nor at time of diagnosis. For all enrolled patient, there is evidence of inflammation detected by positive HsCRP. All patients were in stable state maintained using inhaled budesonide /formeterol (160/4.5) twice daily and/or long acting anticholinergic and/or phyllocontine (225 mg) at night. Those who are excluded from the trial included any patient refused the participation in the study or those with no obvious diagnosis of COPD or patients presenting during exacerbation episodes and patients not under regular treatment. The 90 patients were divided equally and randomly into 3 groups: Group 1: Thirty patients receive atorvastatin 40 mg at night Group 2: Thirty patients receive atorvastatin 10 mg at night Group 3: Thirty patients receive placebo treatment in addition to their baseline treatment for all 3 groups. All patients are assessed at zero time for severity using chronic obstructive airway disease assessment test (CAT) score (clinical questions used to assess the control briefly by the patients word), spirometry in addition to their initial liver function tests, creatinine phosphokinase and HsCRP. A second assessment performed at 6 months' time for all the above initial evaluation as well as inquiring for COPD-induced hospitalization, exacerbations attacks and over-all mortality, in addition to adverse effect like myopathy or hepatitis picture necessitate medical seek. Primary end-points were reduction in HsCRP (inflammatory markers), FEV1 changes (physiological markers) and CAT score changes (clinical markers for diseases control). Secondary end-points were frequency of hospitalization, exacerbation and over-all mortality. Safety issues were also assessed like GIT effect, CNS effect as dizziness and amnesia, liver effect and myopathy. Statistical analysis was carried out using SPSS version 17. Categorical variables were presented as frequencies and percentages. Continuous variables were presented as (Mean ± SD). Paired t-test was used to compare means between paired numerical readings when difference between readings was normally distributed. Wilcoxon Signed Ranks Test was used to compare means between paired numerical readings when difference between readings was not normally distributed. A p-value of ≤ 0.05 was considered as significant.
Results

Patients' demography
As shown in table 1, the majority of patients were males and old age as the risk factor is smoking, which have a stronger effect in male and in elderly. Regarding frequency of hospital admissions in the 6 months of study; the majority of the patients does not need hospitalization as most of them could be treated as an outpatient as shown in (Figure 1 ). 
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The distribution of patients with COPD according to frequency of exacerbations in the 6 months of the study is shown in (Figure 2 ) where the majority showed 1-2 attacks of exacerbation in a relatively short period, which represent the heavy burden of this disease on the health budget. The distribution of patients with COPD according to side effects developed in the study duration: Both groups showed side effects, which mean that these effects may be not related to the drug treatment alone but also to the disease itself as shown in (Table 2) . (Tables 3 and Table 4 ) which indicate matching of the three groups. Table 3 . The mean differences of age by study groups *p value ≤ 0.05 was significant **p value ≤ 0.01 was highly significant Table 4 . The Distribution of patients with COPD according to age with each study groups Table 5 shows mean differences of HsCRP, CATscore and FEV1 after treatment by study groups, there were significant differences between means of HsCRP and FEV1 by study groups, while there were no significant differences between means of CAT-score by study groups. Table 7 . The mean differences of HsCRP, CAT-Score and FEV1 before and after low dose of statin Note: Two patients from this group died during follow up, *p value ≤ 0.05 was significant Table 8 . Association between patients' groups and frequency of exacerbation or hospital admissions *p value ≤ 0.05 was significant Table 9 . Association between study groups and mortality *p value ≤ 0.05 was significant
Gender
Discussion
The majority of patients (61.2%) does not need hospitalization despite that 68.9% show single exacerbation, which means that much patients with mild COPD exacerbation can be treatment as outpatients, this finding is consistent with most of the clinical practice data (18) . Both the overall side effects seen in the study groups (statin or the placebo groups) are more in the GI upset and muscular effect, this was expected finding as the both can be induced by the drugs or the disease itself (19) . The overall mortality is 10% over 6 months, 5 patients of them in the placebo arm but the difference is not statistically significant, this finding is higher than Kirchmayer et al, which may be due to small sample size. The effect on all-cause mortality is a gray area because it is possible that there are potential beneficial effects of statins on cardiovascular comorbidities as it is known that smoking is a causative factor in the majority of patients with COPD and in the (20) . The finding from the current study that statins not reduced mortality in patients with COPD were inconsistent with most of the included studies (21, 22) . However, a large multi-centre randomized clinical trial showed that statins had no effect on COPD exacerbations, which was consistent with this finding (23) . Several reasons might be accountable for this; only moderate-to-severe COPD patients were included in these studies and it is unclear whether statins were beneficial for patients with less impairment. In addition, the mean followed-up time was around 2 years, which might be a significantly different compared to the short-term effect in this study. Although the statin show a significant improvement in the both treated groups regarding the HsCRP, CAT score and FEV1 after 6 months of treatment, this improvement fail to show significant effect on CAT score when compared to placebo group i.e. the statin treatment not show symptomatic improvement measured by CAT score over placebo treatment. These findings consistent with some studies and inconsistent with others and that because it is depend on the study criteria and design as seen in Carlson et al study (24) . The statin treatment showed significant improvement of hospitalization, number of exacerbations but not mortality, again this finding is not proved yet (23, 26) . The useful effect of statin was shown both in high and low dose in all primary endpoints but the side effects were higher in high dose arm as expected as the statin side effects are dose dependent (27) . In conclusion; atorvastatin use in COPD may have some beneficial effects on the disease profile mainly on the inflammatory aspects in addition to possible another useful effect on lung functions decline, frequency of exacerbations, hospitalization and even symptomatology of the patients. However, there is no clear benefits of statin in all-cause mortality outcome. The gastrointestinal and muscular adverse effects were significantly higher in the treatment groups patients. It is recommended now to study the statin use in COPD in larger study with a longer duration and use other family drugs members and other doses to see whether it is group or drug related effects as well as using other inflammatory markers like interleukins (IL6) or tumor necrosis factor (TNF) to confirm their effect of the treatment in COPD.
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